MedTrace Logo

REVERSE-Long COVID-19 With Baricitinib Study

NCT05858515 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2025-01-31

No results posted yet for this study

Summary

REVERSE-LC is a phase 3 trial of baricitinib versus placebo in adults with neurocognitive impairment (a form of Alzheimer's Disease and Related Dementias or ADRD) or cardiopulmonary symptoms due to Long COVID.

Conditions

  • Post-Acute COVID-19 Syndrome

Interventions

DRUG

Baricitinib 4 MG

Nonproprietary name: Baricitinib

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • E. Wesley Ely, MD, MPH · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-21
Primary Completion
2027-12-31
Completion
2029-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05858515 on ClinicalTrials.gov